Clinical Trial Update: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing CagriSema to tirzepatide in adults with Type 2 diabetes on metformin (with or without an SGLT2 inhibitor) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• CagriSema (cagrilintide/semaglutide)
• Tirzepatide (tirzepatide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED